Epidemiologist Erin Bowles, MPH, is looking at cancer screening and treatment from many different perspectives. Her research brings new insight into cancer risk factors, diagnosis, treatment, and survivorship, while helping improve cancer care for patients and families.
Erin received an R50 mid-career research award from the National Cancer Institute (NCI). This award is given to cancer researchers who have demonstrated successes and contributions to cancer research as a non-principal investigator. As a key member of 2 large cancer collaborations — the NCI's Breast Cancer Surveillance Consortium and the Health Care Systems Cancer Research Network (CRN) — Erin has developed diverse expertise that includes reading mammograms for breast density and using administrative data to understand patterns of care in cancer treatment.
Her current work includes:
Erin’s experience working with large observational cohorts and collaborations with numerous study teams over the past 20 years has provided her with expertise in data collection and quality control for many subject areas. She is also a manager of the Collaborative Science Division at KPWHRI, providing leadership, supervision, mentorship, and support to junior faculty.
Breast cancer; colorectal cancer; multiple myeloma; thyroid cancer; pancreatic cancer; biostatistics; epidemiology; mammography; mammographic breast density; cancer treatment; cancer screening and surveillance; automated data collection; quality of care; medication use; care coordination; administrative data
Access to care; health disparities; health outcomes research; quality of life; measurement of change in health care systems; practice variation
Menopause; hormone replacement therapy (HRT); breast cancer
Cognitive health and dementia; biostatistics; epidemiology; medication use; cancer
Pharmacoepidemiology; observational study research methods; chemotherapy; radiation exposure
Haas CB, Bowles EJA, Lee JM, Specht J, Buist DSM. Accuracy of tumor registry versus pharmacy dispensings for breast cancer adjuvant endocrine therapy. Cancer Causes Control. 2022 Jul 7. doi: 10.1007/s10552-022-01603-9. [Epub ahead of print]. PubMed
Sarma EA, Thompson MJ, Bowles EJA, Burnett-Hartman AN, Hubbard RA, Yu O, Chubak J. Patient and tumour characteristics of screening-age adults diagnosed with screen-detected versus symptomatic colon cancer. Colorectal Dis. 2022 Jun 23. doi: 10.1111/codi.16232. PubMed
Nyante SJ, Abraham L, Aiello Bowles EJ, Lee CI, Kerlikowske K, Miglioretti DL, Sprague BL, Henderson LM. Diagnostic mammography performance across racial and ethnic groups in a national network of community-based breast imaging facilities. Cancer Epidemiol Biomarkers Prev. 2022 Jun 17:OF1-OF10. doi: 10.1158/1055-9965.EPI-21-1379. Online ahead of print. PubMed
Ramin C, Gierach GL, Abubakar M, Veiga LHS, Vo JB, Curtis RE, Bowles EJ, Feigelson HS, Buist DSM, de Gonzalez AB, Bodelon C. The influence of treatment on hormone receptor subgroups and breast cancer-specific mortality within US integrated healthcare systems. Cancer Causes Control. 2022 Jul;33(7):1019-1023. doi: 10.1007/s10552-022-01589-4. Epub 2022 May 18. PubMed
Abubakar M, Mullooly M, Nyante S, Pfeiffer RM, Aiello Bowles EJ, Cora R, Bodelon C, Butler E, Butcher D, Sternberg L, Troester MA, Weinmann S, Sherman M, Glass AG, de Gonzalez AB, Gierach GL. Mammographic density decline, tamoxifen response, and prognosis by molecular characteristics of estrogen receptor-positive breast cancer. JNCI Cancer Spectr. 2022 May 2;6(3):pkac028. doi: 10.1093/jncics/pkac028. PubMed
Bowles EJA, Ramin C, Buist DSM, Feigelson HS, Weinmann S, Veiga LHS, Bodelon C, Curtis RE, Vo JB, Berrington de Gonzalez A, Gierach GL. Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016. Breast Cancer Res Treat. 2022 May;193(1):203-216. doi: 10.1007/s10549-022-06561-z. Epub 2022 Mar 11. PubMed
The division contributes to research across the institute with methodological and subject matter expertise.
Kaiser Permanente Washington has been part of the national Breast Cancer Surveillance Consortium since 1994. Learn about the Kaiser Permanente Washington Breast Cancer Surveillance Registry here.
How KPWHRI is contributing to better cancer screening and better outcomes for patients.
Cell by cell, scientists are building a high-resolution map of brain changes in Alzheimer’s disease.
Study suggests disparities at screening sites may influence lag in follow-ups.